Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Childre… (NCT04821856) | Clinical Trial Compass
CompletedPhase 2
Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
Australia132 participantsStarted 2021-05-11
Plain-language summary
This is a multi-site, double-blind, parallel group, randomized, placebo-controlled study of 140 participants comparing oral purified cannabidiol isolate (CBD) with placebo in reducing Severe Behavioral Problems (SBP) at 8 weeks in children aged 6 - 18 years with Intellectual Disability (ID). Eligible participants will be randomized 1:1 to receive either CBD or placebo.
Who can participate
Age range6 Years – 18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females aged 6 - 18 years of age;
✓. DSM-5 diagnosis of intellectual disability (ID):
✓. Full scale IQ \< 70 on standardized cognitive assessment. Testing results must be sighted by the investigators and performed within two years of enrollment. In the event that records of prior testing are unavailable or the assessment was more than 2 years prior, IQ will be estimated using the Wechsler Abbreviated Scale of Intelligence-II.
✓. Deficit in adaptive function (basis for severity rating of ID in DSM-5) in at least one activity of life on the Vineland Adaptive Behavior Scales (derives scores in Communication, Daily Living Skills and Socialization domains, and a Global Adaptive score). If records of prior testing are unavailable or the assessment was more than 2 years prior, this will be completed by the parent or guardian.
✓. SBP: Defined as scores of:
✓. 18 or higher on the Aberrant Behavior Checklist-Irritability subscale (ABC-I), and
✓. moderate or higher on the Clinical Global Impressions-Severity scale;
✓. No changes in either medication or other interventions in the 4 weeks prior to randomization, and intention to remain on same dose for the duration of the study;
Exclusion criteria
✕. Non-English speaking parents;
✕. Psychosis;
✕
What they're measuring
1
Mean difference between the cannabidiol 100mg/ml and placebo arms on the Aberrant Behavior Checklist-Irritability (ABC-I) subscale total score at day 64
Timeframe: At day 64 (end of maintenance treatment period)